World Investment Advisors Lowers Stock Position in Cigna Group $CI

World Investment Advisors cut its position in shares of Cigna Group (NYSE:CI) by 27.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,698 shares of the health services provider’s stock after selling 2,155 shares during the period. World Investment Advisors’ holdings in Cigna Group were worth $1,568,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Beacon Financial Strategies CORP purchased a new stake in Cigna Group during the fourth quarter worth $28,000. Collier Financial purchased a new stake in Cigna Group during the third quarter worth $34,000. Lodestone Wealth Management LLC acquired a new position in Cigna Group during the fourth quarter worth $32,000. Activest Wealth Management raised its position in Cigna Group by 1,050.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the health services provider’s stock worth $38,000 after acquiring an additional 126 shares during the period. Finally, Founders Capital Management raised its position in Cigna Group by 53.0% during the third quarter. Founders Capital Management now owns 153 shares of the health services provider’s stock worth $44,000 after acquiring an additional 53 shares during the period. 86.99% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Nicole S. Jones sold 2,307 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $288.91, for a total value of $666,515.37. Following the completion of the sale, the insider directly owned 32,647 shares in the company, valued at $9,432,044.77. This represents a 6.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Everett Neville sold 1,719 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $288.91, for a total transaction of $496,636.29. Following the completion of the sale, the insider owned 5,670 shares of the company’s stock, valued at $1,638,119.70. This trade represents a 23.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 205,904 shares of company stock worth $60,277,068 over the last three months. Insiders own 0.60% of the company’s stock.

Analysts Set New Price Targets

CI has been the subject of a number of research analyst reports. UBS Group restated a “buy” rating and set a $375.00 price objective on shares of Cigna Group in a research report on Monday, February 9th. Sanford C. Bernstein upped their price objective on shares of Cigna Group from $358.00 to $371.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Wells Fargo & Company upped their price objective on shares of Cigna Group from $300.00 to $305.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. Cantor Fitzgerald upped their price objective on shares of Cigna Group from $325.00 to $340.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Finally, Barclays upped their price objective on shares of Cigna Group from $303.00 to $310.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $338.35.

Cigna Group Price Performance

Shares of NYSE CI opened at $285.25 on Friday. The firm has a 50-day simple moving average of $274.95 and a 200-day simple moving average of $275.97. The stock has a market capitalization of $75.46 billion, a price-to-earnings ratio of 12.09, a price-to-earnings-growth ratio of 1.00 and a beta of 0.30. The company has a quick ratio of 0.73, a current ratio of 0.73 and a debt-to-equity ratio of 0.69. Cigna Group has a 52 week low of $239.51 and a 52 week high of $338.89.

Cigna Group (NYSE:CI) last issued its earnings results on Thursday, April 30th. The health services provider reported $7.79 EPS for the quarter, beating analysts’ consensus estimates of $7.60 by $0.19. The business had revenue of $68.52 billion during the quarter, compared to analysts’ expectations of $66.29 billion. Cigna Group had a net margin of 2.26% and a return on equity of 19.75%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business earned $6.74 earnings per share. Cigna Group has set its FY 2026 guidance at 30.350- EPS. On average, equities analysts predict that Cigna Group will post 30.39 earnings per share for the current fiscal year.

Cigna Group Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 18th. Stockholders of record on Thursday, June 4th will be given a $1.56 dividend. This represents a $6.24 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Thursday, June 4th. Cigna Group’s dividend payout ratio is 26.45%.

Cigna Group Company Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.